Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
IL-33 Signaling Pathways
Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine.
Cayrol C, Girard JP. Cytokine. 2022;156(155981):1-15.
A large-scale, consortium-based genomewide association study of asthma.
Moffatt MF, et al. N Engl J Med. 2010;363(13):1211-1221.
Rabe KF, et al. Eur Respir J. 2024; 64: Suppl 68, OA3645.
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF, et al. Lancet Respir Med. 2021;9(11):1288-1298.
Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD
Calderon AA, et al. Eur Respir Rev. 2023;32(167):220144.
Involvement of IL-33 in the pathogenesis and prognosis of major respiratory viral infections: future perspectives for personalized therapy.
Murdaca G, et al. Biomedicines. 2022;10(3):715.
IL-33 and the cytokine storm in COVID-19: from a potential immunological relationship towards precision medicine.
Furci F, et al. Int J Mol Sci. 2022;23(23):145322.
The paradoxical effect of IL-6 and implications for the use of tocilizumab in Covid-19 patients.
Bruzzese V, Lazzarino AI. Med Hypotheses. 2020;144:110284
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
Yousuf AJ, et al. Lancet Respir Med. 2022;10(5):469-477.
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4.
Singh D, et al. Eur Respir J 2025; in press.
S90 FRONTIER-3: a randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma.
Corren J, et al. Thorax. 2024;79:A65-A66.
A randomized phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalized with COVID-19: ACCORD-2.
Wilkinson T, et al. ERJ Open Res. 2023;9(5):00249-2023.
CLINICAL PRACTICE GUIDELINES
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2025 report.
Global Strategy for Asthma Management and Prevention.
Global Initiative for Asthma, 2024.
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
National Institute of Health (NIH)
Interleukin-33 and Lower Tract Respiratory Diseases
Moving From Pathophysiology to Management
| Faculty: | Jonathan M. Hand, MD; Professor Dave Singh MD, FERS, FBPhS; Professor Tom Wilkinson MA Cantab MBBS PhD FRCP FERS |
| Release: | 05/19/2025 |
| Expiration: | 06/19/2025 |
